Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Active Not Recruiting Phase 2 Trials for Oxaliplatin (DB00526)
Also known as: Resectable Pancreatic Ductal Adenocarcinoma
Indication | Status | Phase |
---|---|---|
DBCOND0115304 (Resectable Pancreatic Ductal Adenocarcinoma (PDAC)) | Active Not Recruiting | 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | Treatment |